For the Benefit of All: Optimizing Cancer Clinical Trials by Enrolling Diverse Participants

You put so much into staging a high-integrity cancer clinical trial.

But if diverse participants don’t enroll or stay in that trial, the validity of results — and the promise of treatment — are in question.

“For the Benefit of All” is a one and a half-day seminar that gives you new strategies and tools to enroll more patients from under-represented populations in your cancer trials.

We’ll explore how to:

• design your cancer clinical trial to serve people of different races, ethnicities, places of residence and socio-economic statuses;
• communicate details of the trial so that all audiences understand how it works – and how it might benefit them; and
• eliminate barriers that keep historically underrepresented groups from enrolling or staying in the trial.

Tailored to clinical trial managers, cancer researchers, physicians and research teams, “For the Benefit of All” builds on the dialogue held at the 2022 summit “Addressing Disparities in Cancer Clinical Trials.”

February 21-22, 2024 | Georgia International Convention Center in College Park

REGISTER HERE | WORKING AGENDA

Registration deadline is February 14, 2024. For sponsorship opportunities, please email Kristina Forbes at kforbes@georgiacore.org. Click here to open the sponsorship packet.

HOTEL BLOCK

We have reserved a discounted room block at  Tru/Home2 Suites by Hilton Hotels. Click here to book.

---

CME/CE DISCLOSER

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Morehouse School of Medicine and Georgia CORE. The Morehouse School of Medicine is accredited by the ACCME to provide continuing medical education for physicians The Morehouse School of Medicine designates this live activity for a maximum of up to 7.75 AMA PRA Category 1 credit (s) ™. Physicians should only claim credit commensurate with the extent to their participation in the activity.

At the conclusion of this activity, participants should be able to:

1. Describe strategies for reducing bias that may affect clinical trial accrual.
2. Discuss the importance of addressing clinical research design to eliminate barriers to clinical trial participation.
3. Use various communications strategies to reach underrepresented patient populations for cancer clinical trial accrual.
4. Explain and use concepts of Decentralized studies to reach minority and rural patients populations for cancer clinical trial accrual

Morehouse School of Medicine (MSM) in accordance with ACCME guidelines requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MSM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and the appropriateness of patient care recommendations. Full disclosure of speaker relationships will be made at this activity.

In accordance with the ACCME Standards for Commercial Support of CME, the Morehouse School of Medicine has implemented mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity.

This information provided at this CME activity is for continuing education purposes and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.